{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Madore MR"],"funding":["NIA NIH HHS","NIMH NIH HHS","RRD VA","CSRD VA"],"pagination":["671-678"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8667345"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["297"],"pubmed_abstract":["<h4>Background</h4>Repetitive transcranial magnetic stimulation (TMS) is an evidence-based treatment for pharmacoresistant major depressive disorder (MDD), however, the evidence in veterans has been mixed. To this end, VA implemented a nationwide TMS program that included evaluating clinical outcomes within a naturalistic design. TMS was hypothesized to be safe and provide clinically meaningful reductions in MDD and posttraumatic stress disorder (PTSD) symptoms.<h4>Methods</h4>Inclusion criteria were MDD diagnosis and standard clinical TMS eligibility. Of the 770 patients enrolled between October 2017 and March 2020, 68.4% (n = 521) met threshold-level PTSD symptom criteria. Treatments generally used standard parameters (e.g., left dorsolateral prefrontal cortex, 120% motor threshold, 10 H"],"journal":["Journal of affective disorders"],"pubmed_title":["Prefrontal transcranial magnetic stimulation for depression in US military veterans - A naturalistic cohort study in the veterans health administration."],"pmcid":["PMC8667345"],"funding_grant_id":["I01 CX002088","P30 AG059307","R01 MH120126","I50 RX002864"],"pubmed_authors":["George MS","Green LC","Philip NS","Kozel FA","Holtzheimer PE","Madore MR","Williams LM","Yesavage JA"],"additional_accession":[]},"is_claimable":false,"name":"Prefrontal transcranial magnetic stimulation for depression in US military veterans - A naturalistic cohort study in the veterans health administration.","description":"<h4>Background</h4>Repetitive transcranial magnetic stimulation (TMS) is an evidence-based treatment for pharmacoresistant major depressive disorder (MDD), however, the evidence in veterans has been mixed. To this end, VA implemented a nationwide TMS program that included evaluating clinical outcomes within a naturalistic design. TMS was hypothesized to be safe and provide clinically meaningful reductions in MDD and posttraumatic stress disorder (PTSD) symptoms.<h4>Methods</h4>Inclusion criteria were MDD diagnosis and standard clinical TMS eligibility. Of the 770 patients enrolled between October 2017 and March 2020, 68.4% (n = 521) met threshold-level PTSD symptom criteria. Treatments generally used standard parameters (e.g., left dorsolateral prefrontal cortex, 120% motor threshold, 10 H","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-26T13:22:43.889Z","creation":"2025-04-06T14:16:06.656Z"},"accession":"S-EPMC8667345","cross_references":{"pubmed":["34687780"],"doi":["10.1016/j.jad.2021.10.025"]}}